Table 1.
Effect of 5-BDBD on the mRNA levels of P2X4R, NLRP3, caspase-1, IL-1β, and IL-18 in the substantia nigra pars compacta
| Gene | Control | 6-OHDA | 5-BDBD | 5-BDBD+6-OHDA |
|---|---|---|---|---|
| P2X4R | 1.031±0.104 | 3.217±0.09** | 1.070±0.044 | 2.741±0.094††‡‡ |
| NLRP3 | 1.004±0.037 | 3.933±0.111** | 1.033±0.034 | 3.039±0.057††‡‡ |
| Caspase-1 | 1.011±0.048 | 3.961±0.132** | 1.056±0.053 | 3.007±0.096††‡‡ |
| IL-1β | 1.033±0.058 | 3.876±0.099** | 1.047±0.041 | 3.068±0.071††‡‡ |
| IL-18 | 1.007±0.047 | 3.437±0.123** | 1.029±0.045 | 2.625±0.117††‡‡ |
Control group: after 1 week of pretreatment with 0.9% physiological saline, ascorbic acid was injected into the SNpc stereotactically; 6-OHDA group: after 1 week of pretreatment with 0.9% physiological saline, 6-OHDA was injected into the SNpc stereotactically; 5-BDBD group: after 1 week of pretreatment with 5-BDBD, ascorbic acid was injected into the SNpc stereotactically; 5-BDBD + 6-OHDA group: after 1 week of pretreatment with 5-BDBD, 6-OHDA was injected into the SNpc stereotactically. Data are expressed as mean ± SEM (n = 7 mice/group). **P < 0.01, vs. control group; ††P < 0.01, vs. 5-BDBD group; ‡‡P < 0.01, vs. 6-OHDA group (one-way analysis of variance followed by the Student–Newman–Keuls test). 5-BDBD: 5-(3-Bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2-one; 6-OHDA: 6-hydroxydopamine; IL: interleukin; NLRP3: Nod-like receptor family protein 3; P2X4R: P2X4 receptor; SNpc: substantia nigra pars compacta.